Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d’Ivoire | Ekouevi et al. Journal of the International AIDS Society 2010 13 28 http content 13 1 28 JOURNALOF THE INTERNATIONAL AIDS SOCIETY SHORT REPORT Open Access Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1 a study in Côte d Ivoire 4 Didier K Ekouevi 1 Patrick A Coffie 1 Marie-Laure Chaix Besigin Tonwe-Gold 1 Clarisse Amani-Bosse Valériane Leroy1 2 Elaine J Abrams6 Frangois Dabis1 2 Abstract Background Information is currently limited on the long-term follow up of HIV-1 infected women who are on highly active antiretroviral therapy HAART that contains nevirapine and lamivudine and who were previously exposed to antiretroviral drugs for the prevention of mother to child transmission PMTCT of HIV. Methods We studied the 36-month immunological response to HAART in HIV-1 infected women in Côte d Ivoire. The women were previously exposed to antiretroviral drug regimens for PMTCT including single-dose nevirapine and or short-course zidovudine with or without lamivudine. All HAART regimens included a non-nucleoside reverse transcriptase inhibitor. Results At 36 months the median absolute increase in CD4 T cell count was 359 cells mm3 IQR 210-466 in 200 women who had undergone 36-month follow-up visits 359 cells mm3 IQR 222-491 in 88 women not exposed to PMTCT antiretrovirals and 363 cells mm3 IQR 200-464 in 112 women exposed to at least one antiretroviral PMTCT regimen. Overall 49 of the 247 women who initiated HAART met the immunological failure criteria at least once during follow up. The overall probability of immunological failure was 95 CI at 12 months and 95 CI at 36 months. No difference was observed according to the presence or absence of resistance mutations to nevirapine or lamivudine in women tested at four weeks postpartum. In addition at 36 months 23 of women were lost to follow up dead or had .
